drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified CAR T cells)
drug_description
Gene-modified gamma-delta T cells engineered to express an anti-CD19 chimeric antigen receptor. Binding to CD19 on B-lineage cells triggers T-cell activation and perforin/granzyme-mediated cytotoxicity, leading to depletion of CD19+ B cells and plasmablasts, reduced autoantibody production, and modulation of antigen presentation and inflammatory cytokine signaling.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene-modified gamma-delta T cells expressing an anti-CD19 chimeric antigen receptor bind CD19 on B-lineage cells, triggering CAR-mediated activation and perforin/granzyme cytotoxicity. This depletes CD19+ B cells and plasmablasts, reducing autoantibody production and modulating antigen presentation and inflammatory cytokine signaling.
drug_name
UTAA09 (CD19-directed CAR gamma-delta T cells)
nct_id_drug_ref
NCT06417398